IRCT20150622022869N11招募中3 期
Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients
Yasouj University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •A patient who underwent endoscopy and has peptic ulcer disease (PUD).
- •Patients with dyspepsia without endoscopic indication have a positive Helicobacter diagnostic test, including Helicobacter stool antigen test and....
- •Patients with maltoma
- •Endoscopy patients with nud (non-ulcer dyspepsia) and patients with a history of cancer in their first degree relatives will be included in the study.
- •Patients who have a history of pud and are Helicobacter positive and are taking NSAID
- •Treatment-resistant dyspepsia
- •Patient satisfaction
排除标准
- •Previous history of H pylori treatment
- •Allergy to antibiotics
- •Allergy to PPI
- •History of gastrectomy
- •Having gastric cancer
- •pregnant women
- •Taking antibiotics in the last month
- •Taking PPI or h2blocker in the last two weeks
- •Chronic liver, kidney or lung disease
- •History of Fauvism
研究者
相似试验
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSEUCTR2005-002892-34-IEAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-GRAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-PTAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-EEAstraZeneca SAS1,150
进行中（未招募）
1 期
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome.Comparación de los Efectos Observados en el cociente ApoB/ApoA-I, tras el Uso de Rosuvastatina y Atorvastatina en pacientes con Síndrome Coronario Agudo - CENTAURUS - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-ESAstraZeneca SAS1,150